Nanoparticle delivery of donor antigens for transplant tolerance in allogeneic islet transplantation

Biomaterials

Volumn 35, Issue 31, 2014, Pages 8887-8894

  Bryant, Jane ^a   Hlavaty, Kelan A ^b,c   Zhang, Xiaomin ^a   Yap, Woon Teck ^b,c   Zhang, Lei ^a   Shea, Lonnie D ^a,b,c   Luo, Xunrong ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Northwestern University   (United States)

Author keywords

1 ethyl 3 (3' dimethylaminopropyl) carbodiimide (ECDI); Allogeneic cells; Islet; Poly(lactide co glycolide) (PLG); Tolerance; Transplantation

Indexed keywords

CELLS; FITS AND TOLERANCES; TRANSPLANTATION (SURGICAL);

ALLOGENEIC CELLS; CARBODIIMIDES; CARRIER FOR DELIVERIES; COMBINATION THERAPY; ISLET; ISLET TRANSPLANTATION; MAJOR HISTOCOMPATIBILITY COMPLEX; POLY LACTIDE-CO-GLYCOLIDE;

ANTIGENS;

ANTIGEN; NANOPARTICLE; POLYGLACTIN; RAPAMYCIN; 1 (3 DIMETHYLAMINOPROPYL) 3 ETHYLCARBODIIMIDE; DRUG CARRIER; IMMUNOSUPPRESSIVE AGENT;

ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEASIBILITY STUDY; GRAFT REJECTION; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PHAGOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TRANSPLANTATION TOLERANCE; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG EFFECTS; IMMUNOLOGICAL TOLERANCE; PROCEDURES;

MURINAE; MUS;

ANIMALS; ANTIGENS; DRUG CARRIERS; ETHYLDIMETHYLAMINOPROPYL CARBODIIMIDE; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MICE, INBRED BALB C; NANOPARTICLES; POLYGLACTIN 910; SIROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84905449444     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.06.044     Document Type: Article

References (36)

1. Mason C., Brindley D.A., Culme-Seymour E.J., Davie N.L. Cell therapy industry: billion dollar global business with unlimited potential. Regen Med 2011, 6(3):265-272.
2. Fischbach M.A., Bluestone J.A., Lim W.A. Cell-based therapeutics: the next pillar of medicine. Sci Transl Med 2013, 5(179):179ps7.
3. Mason C., Manzotti E. Regenerative medicine cell therapies: numbers of units manufactured and patients treated between 1988 and 2010. Regen Med 2010, 5(3):307-313.
4. Shapiro A.M., Lakey J.R., Ryan E.A., Korbutt G.S., Toth E., Warnock G.L., et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000, 343(4):230-238.
5. Nanji S.A., Shapiro A.M. Islet transplantation in patients with diabetes mellitus: choice of immunosuppression. BioDrugs 2004, 18(5):315-328.
6. Scandling J.D., Busque S., Dejbakhsh-Jones S., Benike C., Millan M.T., Shizuru J.A., et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 2008, 358(4):362-368.
7. Kawai T., Cosimi A.B., Spitzer T.R., Tolkoff-Rubin N., Suthanthiran M., Saidman S.L., et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008, 358(4):353-361.
8. Leventhal J., Abecassis M., Miller J., Gallon L., Ravindra K., Tollerud D.J., et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med 2012, 4(124):124ra28.
9. Bolling S.F., Lin H., Wei R.Q., Turka L.A. Preventing allograft rejection with CTLA4IG: effect of donor-specific transfusion route or timing. J Heart Lung Transpl 1996, 15(9):928-935.
10. Luo X., Pothoven K.L., McCarthy D., DeGutes M., Martin A., Getts D.R., et al. ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term survival of islet transplants via two distinct mechanisms. Proc Natl Acad Sci U S A 2008, 105(38):14527-14532.
11. Kheradmand T., Wang S., Bryant J., Tasch J.J., Lerret N., Pothoven K.L., et al. Ethylenecarbodiimide-fixed donor splenocyte infusions differentially target direct and indirect pathways of allorecognition for induction of transplant tolerance. J Immunol 2012, 189(2):804-812.
12. Getts D.R., Martin A.J., McCarthy D.P., Terry R.L., Hunter Z.N., Yap W.T., et al. Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat Biotechnol 2012, 30(12):1217-1224.
13. Kazzaz J., Singh M., Ugozzoli M., Chesko J., Soenawan E., O'Hagan D.T. Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. J Control Release 2006, 110(3):566-573.
14. Wendorf J., Chesko J., Kazzaz J., Ugozzoli M., Vajdy M., O'Hagan D., et al. A comparison of anionic nanoparticles and microparticles as vaccine delivery systems. Hum Vaccin 2008, 4(1):44-49.
15. Stern M., Ulrich K., Geddes D.M., Alton E.W. Poly (D, L-lactide-co-glycolide)/DNA microspheres to facilitate prolonged transgene expression in airway epithelium in vitro, ex vivo and in vivo. Gene Ther 2003, 10(16):1282-1288.
16. Jain S., O'Hagan D.T., Singh M. The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant. Expert Rev Vaccines 2011, 10(12):1731-1742.
17. Wacker M. Nanocarriers for intravenous injection-the long hard road to the market. Int J Pharm 2013, 457(1):50-62.
18. Gentile P., Chiono V., Carmagnola I., Hatton P.V. An overview of poly(lactic-co-glycolic) acid (PLGA)-based biomaterials for bone tissue engineering. Int J Mol Sci 2014, 15(3):3640-3659.
19. Luo X., Yang H., Kim I.S., Saint-Hilaire F., Thomas D.A., De B.P., et al. Systemic transforming growth factor-beta1 gene therapy induces Foxp3+ regulatory cells, restores self-tolerance, and facilitates regeneration of beta cell function in overtly diabetic nonobese diabetic mice. Transplantation 2005, 79(9):1091-1096.
20. Hunter Z., McCarthy D.P., Yap W.T., Harp C.T., Getts D.R., Shea L.D., et al. A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease. ACS Nano 2014, 8(3):2148-2160.
21. Lutterotti A., Yousef S., Sputtek A., Sturner K.H., Stellmann J.P., Breiden P., et al. Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci Transl Med 2013, 5(188):188ra75.
22. Watschinger B. How T cells recognize alloantigen: evidence for two pathways of allorecognition. Nephrol Dial Transpl 1995, 10(9):1556-1558.
23. Sivaganesh S., Harper S.J., Conlon T.M., Callaghan C.J., Saeb-Parsy K., Negus M.C., et al. Copresentation of intact and processed MHC alloantigen by recipient dendritic cells enables delivery of linked help to alloreactive CD8 T cells by indirect-pathway CD4 T cells. J Immunol 2013, 190(11):5829-5838.
24. Lacotte S., Borot S., Ferrari-Lacraz S., Villard J., Demuylder-Mischler S., Oldani G., et al. Posttransplant cellular immune reactivity against donor antigen correlates with clinical islet transplantation outcome: towards a better posttransplant monitoring. Cell Transpl 2012, 21(11):2339-2350.
25. Keegan M.E., Falcone J.L., Leung T.C., Saltzman W.M. Biodegradable microspheres with enhanced capacity for covalently bound surface ligands. Macromolecules 2004, 37(26):9779-9784.
26. Makhlouf L., Yamada A., Ito T., Abdi R., Ansari M.J., Khuong C.Q., et al. Allorecognition and effector pathways of islet allograft rejection in normal versus nonobese diabetic mice. J Am Soc Nephrol 2003, 14(8):2168-2175.
27. Suchin E.J., Langmuir P.B., Palmer E., Sayegh M.H., Wells A.D., Turka L.A. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol 2001, 166(2):973-981.
28. Jiang S., Herrera O., Lechler R.I. New spectrum of allorecognition pathways: implications for graft rejection and transplantation tolerance. Curr Opin Immunol 2004, 16(5):550-557.
29. Terada N., Lucas J.J., Szepesi A., Franklin R.A., Domenico J., Gelfand E.W. Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle. J Cell Physiol 1993, 154(1):7-15.
30. Augustine J.J., Bodziak K.A., Hricik D.E. Use of sirolimus in solid organ transplantation. Drugs 2007, 67(3):369-391.
31. Battaglia M., Stabilini A., Roncarolo M.G. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005, 105(12):4743-4748.
32. Berney T., Secchi A. Rapamycin in islet transplantation: friend or foe?. Transpl Int 2009, 22(2):153-161.
33. Bussiere C.T., Lakey J.R., Shapiro A.M., Korbutt G.S. The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells. Diabetologia 2006, 49(10):2341-2349.
34. Zhang N., Su D., Qu S., Tse T., Bottino R., Balamurugan A.N., et al. Sirolimus is associated with reduced islet engraftment and impaired beta-cell function. Diabetes 2006, 55(9):2429-2436.
35. Mercalli A., Sordi V., Ponzoni M., Maffi P., De Taddeo F., Gatti G., et al. Rapamycin induces a caspase-independent cell death in human monocytes. Am J Transpl 2006, 6(6):1331-1341.
36. Woltman A.M., de Fijter J.W., Kamerling S.W., van Der Kooij S.W., Paul L.C., Daha M.R., et al. Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages. Blood 2001, 98(1):174-180.